Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

NCT03952078 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03952078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03952078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Lead sponsor
Corvus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 3, 2019
Completion date
April 30, 2026
Enrollment
151 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell lymphoma